Kesanla intravenous infusion solution 350 mg (donanemab-azbt), manufactured by Eli Lilly Japan, is approved in Japan for adults with early symptomatic Alzheimer’s disease, including mild cognitive impairment and mild dementia with confirmed amyloid pathology. The YJ code is 1190409A1020 and the standard is 350mg 20mL 1 bottle.
Kesanla intravenous infusion solution 350 mg
Need more detailed information?
Contact TASAKI PHARMA for product sourcing, availability, or related support (English support available).